Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding >8 Weeks, Retrospective Case-control Study
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Background: Immunocompromised patients now represent the population most at risk for severe coronavirus disease 2019. Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral shedding was reported in these patients ranging from several weeks up to 9 months. We conducted a bicentric retrospective case-control study to identify risk and prognostic factors associated with persistent viral shedding in immunocompromised patients.
Material and Methods: Symptomatic immunocompromised adults with persistent SARS-CoV-2 viral shedding >8 weeks were retrospectively included between 1 March 2020 and 24 April 2022 at 2 university hospitals in Paris, France, and matched with a control group consisting of symptomatic immunocompromised patients without persistent viral shedding.
Results: Twenty-nine immunocompromised patients with persistent viral shedding were compared with 40 controls. In multivariate analysis, fever and lymphocytopenia (<0.5 G/L) were associated with an increased risk of persistent viral shedding (odds ratio [OR]: 3.3; 95% confidence interval [CI], 1.01-11.09) P = .048 and OR: 4.3; 95% CI, 1.2-14.7; P = .019, respectively). Unvaccinated patients had a 6-fold increased risk of persistent viral shedding (OR, 6.6; 95% CI, 1.7-25.1; P = .006). Patients with persistent viral shedding were at risk of hospitalization (OR: 4.8; 95 CI, 1.5-15.6; P = .008), invasive aspergillosis (OR: 10.17; 95 CI, 1.15-89.8; P = .037) and death (log-rank test <0.01).
Conclusions: Vaccine coverage was protective against SARS-CoV-2 persistent viral shedding in immunocompromised patients. This new group of immunocompromised patients with SARS-CoV-2 persistent viral shedding is at risk of developing invasive aspergillosis and death and should therefore be systematically screened for this fungal infection for as long as the viral shedding persists.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 11(2024), 2 vom: 15. Feb., Seite ofae012 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Melenotte, Cléa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 24.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofae012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368804488 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368804488 | ||
| 003 | DE-627 | ||
| 005 | 20240229150439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofae012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368804488 | ||
| 035 | |a (NLM)38390457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melenotte, Cléa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding >8 Weeks, Retrospective Case-control Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Background: Immunocompromised patients now represent the population most at risk for severe coronavirus disease 2019. Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral shedding was reported in these patients ranging from several weeks up to 9 months. We conducted a bicentric retrospective case-control study to identify risk and prognostic factors associated with persistent viral shedding in immunocompromised patients | ||
| 520 | |a Material and Methods: Symptomatic immunocompromised adults with persistent SARS-CoV-2 viral shedding >8 weeks were retrospectively included between 1 March 2020 and 24 April 2022 at 2 university hospitals in Paris, France, and matched with a control group consisting of symptomatic immunocompromised patients without persistent viral shedding | ||
| 520 | |a Results: Twenty-nine immunocompromised patients with persistent viral shedding were compared with 40 controls. In multivariate analysis, fever and lymphocytopenia (<0.5 G/L) were associated with an increased risk of persistent viral shedding (odds ratio [OR]: 3.3; 95% confidence interval [CI], 1.01-11.09) P = .048 and OR: 4.3; 95% CI, 1.2-14.7; P = .019, respectively). Unvaccinated patients had a 6-fold increased risk of persistent viral shedding (OR, 6.6; 95% CI, 1.7-25.1; P = .006). Patients with persistent viral shedding were at risk of hospitalization (OR: 4.8; 95 CI, 1.5-15.6; P = .008), invasive aspergillosis (OR: 10.17; 95 CI, 1.15-89.8; P = .037) and death (log-rank test <0.01) | ||
| 520 | |a Conclusions: Vaccine coverage was protective against SARS-CoV-2 persistent viral shedding in immunocompromised patients. This new group of immunocompromised patients with SARS-CoV-2 persistent viral shedding is at risk of developing invasive aspergillosis and death and should therefore be systematically screened for this fungal infection for as long as the viral shedding persists | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a death | |
| 650 | 4 | |a hematological diseases | |
| 650 | 4 | |a immunocompromised host | |
| 650 | 4 | |a invasive aspergillosis | |
| 650 | 4 | |a persistent viral shedding | |
| 650 | 4 | |a solid organ transplant recipients | |
| 700 | 1 | |a Chavarot, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a L'Honneur, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Bodard, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Cheminant, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Flahault, Adrien |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Yann |e verfasserin |4 aut | |
| 700 | 1 | |a Burgard, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Dannaoui, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Bougnoux, Marie-Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Parize, Perrine |e verfasserin |4 aut | |
| 700 | 1 | |a Rouzaud, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Scemla, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Canouï, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Lafont, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Vimpere, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Zuber, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Charlier, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Suarez, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Anglicheau, Dany |e verfasserin |4 aut | |
| 700 | 1 | |a Hermine, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Lanternier, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Mouthon, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Lortholary, Olivier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 11(2024), 2 vom: 15. Feb., Seite ofae012 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:ofae012 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofae012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 2 |b 15 |c 02 |h ofae012 | ||